Zoetis ( (ZTS) ) has released its Q3 earnings. Here is a breakdown of the information Zoetis presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zoetis Inc., a leading animal health company, specializes in providing medicines, vaccines, diagnostics, and technologies for veterinarians, pet owners, and livestock producers globally. In its third quarter of 2025, Zoetis reported a revenue increase of 1% to $2.4 billion and a net income rise of 6% to $721 million, showcasing a steady financial performance. The company achieved 4% organic operational growth in revenue and 9% in adjusted net income, reflecting disciplined execution and strategic advancements.
Key financial highlights include adjusted net income of $754 million and adjusted diluted earnings per share of $1.70. Zoetis also revised its full-year 2025 revenue guidance to $9.400 – $9.475 billion, with expectations of 5.5% to 6.5% organic operational revenue growth. The company maintained its guidance for adjusted diluted EPS between $6.30 and $6.40, demonstrating confidence in its operational strategies.
Zoetis continues to innovate with significant product approvals and geographic expansions, including new monoclonal antibody therapies for osteoarthritis pain in pets and expanded parasiticide offerings. The company also enhanced its diagnostics capabilities and livestock product portfolio, emphasizing its commitment to advancing animal care and addressing unmet market needs.
Looking ahead, Zoetis remains focused on leveraging its strong customer relationships, robust pipeline, and manufacturing excellence to drive sustainable growth and value for shareholders. The company anticipates continued success with new product launches and strategic initiatives aimed at reinforcing its market leadership.